PLATO ACT4
Is a randomised phase II trial which compares standard-dose CRT (50.4Gy in 28 fractions) with reduced-dose CRT (41.4Gy in 23 fractions) in patients with intermediate-risk disease, to see if less radiotherapy is able to maintain theexcellent success rates in treating the cancer, while reducing the side effects of treatment.
ACT4 Recruitment
162 Patients – recruitment closed on 01/12/2020.